TITLE

Extended use of a percutaneous left-ventricular assist device without a heparin-based purge solution

AUTHOR(S)
Jennings, Douglas L.; Nemerovski, Carrie W.; Khandelwal, Akshay
PUB. DATE
November 2010
SOURCE
American Journal of Health-System Pharmacy;11/1/2010, Vol. 67 Issue 21, p1825
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. The extended use of an Impella LP 2.5 percutaneous left-ventricular assist device (pVAD) without a heparin-based purge solution in a patient who developed cardiogenic shock after acute myocardial infarction (AMI) is described. Summary. A 58-year-old Asian man with no history of cardiac disease, hypertension, or diabetes mellitus had an AMI and subsequent cardiogenic shock. He was started on dopamine and norepinephrine and transferred to a tertiary care center for rescue percutaneous coronary intervention (PCI). Given that his artery was patent with Thrombolysis In Myocardial Infarction 3 flow, PCI was not attempted. He had an ejection fraction of 25% and mid-distal anteroseptal akinesis. He was transferred to the intensive care unit on intra-aortic balloon pump (IABP) support. The patient's condition continued to deteriorate, and an Impella LP 2.5 pVAD was inserted for additional hemodynamic support and as a bridge to definitive revascularization. To reduce the potential for medication error and decrease the patient's bleeding risk, the purge solution was changed to 20% dextrose injection without heparin and continued at a rate of 15 mL/hr. The patient's hemodynamic values improved, and the pVAD and IABP were continued for the next five days. The patient was successfully anticoagulated with i.v. heparin throughout the remainder of pVAD support. While the patient did develop hemolytic anemia during his device support, there were no thrombotic or bleeding complications. Conclusion. An Impella LP 2.5 pVAD was used for 75 hours with a purge solution that contained no heparin. There were no thrombotic or bleeding complications.
ACCESSION #
54617672

 

Related Articles

  • Therapy of unstable angina with the low molecular weight heparins. Ageno, W.; Turpie, A.G. // Vascular Medicine;2000, Vol. 5 Issue 4, p217 

    Unstable angina is in most cases caused by partial or complete coronary artery occlusion due to the disruption of an atherosclerotic plaque and to thrombus formation. An immediate antithrombotic approach is essential to prevent fatal and non-fatal myocardial infarction, and the combination of...

  • Treat unstable angina with short-term heparin and long-term aspirin. Leibovitch, Eric R. // Modern Medicine;Jan97, Vol. 65 Issue 1, p60 

    Presents an abstract of the study `Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: A meta-analysis,' by A. Oler, M.A. Whooley et al published in the September 11, 1996 issue of the `Journal of the American Medical Association.'

  • Implantable cardioverter defibrillators after acute myocardial infarction: Evidence suggests no overall survival benefit if inserted within 40 days. Liew, Reginald // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;12/4/2010, Vol. 341 Issue 7784, p1174 

    The author analyzes a study which further explained why early insertion of an implantable cardioverter defibrillator soon after acute myocardial infarction may not improve survival. He noted the observation of the study that recurrent myocardial infarction (MI) or cardiac rupture to death was...

  • Low-molecular-weight heparins: Review of their role for unstable angina/non-Q-wave MI. Reinhard, Felicia // Formulary;Dec2000, Vol. 35 Issue 12, p970 

    Explores how the low-molecular-weight heparins' (LMWH) pharmacologic differences from unfractionated heparin (UFH) form the basis for their use in this setting. Enhanced anti-factor Xa:anti-factor IIa ratio of LMWH; Clinical efficacy trials of LMWH for unstable angina/non-Q-wave myocardial...

  • Cost-Effectiveness Analysis of Enoxaparin versus Unfractionated Heparin in the Secondary Prevention of Acute Coronary Syndrome. Brosa, M.; Rubio-TerrĂ©s, C.; Farr, I.; Nadipelli, V.; Froufe, J. // PharmacoEconomics;2002, Vol. 20 Issue 14, p979 

    Background: The Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) and Thrombolysis in Myocardial Infarction (TIMI) 11B studies revealed that enoxaparin reduced the incidence of death, myocardial reinfarction and recurrent angina in patients with acute...

  • Low-molecular-weight heparin is better than unfractionated heparin in unstable angina and...  // Modern Medicine;Oct97, Vol. 65 Issue 10, p18 

    Highlights results of the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events trial. Evidence of the superiority of an alternative to standard heparin treatment for unstable angina or non-Q-wave myocardial infarction; Advantage of the size of enoxaparin's molecules.

  • Battle of the clot busters. Rhein Jr., Reginald // BMJ: British Medical Journal (International Edition);5/12/90, Vol. 300 Issue 6734, p1223 

    Examines the treatments for patients having a heart attack in Italy. Effectiveness of plasminogen activator for heart attack; Introduction of thrombolytic treatment for myocardial infarction; Application of intravenous heparin with activase.

  • Continuing low-weight heparin after MI reduces recurrent events.  // Geriatrics;Oct96, Vol. 51 Issue 10, p56 

    Presents an abstract of a research, `Reduction of Reinfarction and Angina with Use of Low-Molecular-Weight Heparin Therapy After Streptokinase (and heparin) in Acute Myocardial Infarction,' by A. Glick, R. Kornowski, Y. Michowich et al, published in 1996 issue of `American Journal of Cardiology.'

  • Heparin for acute MI is not necessarily the best course.  // Modern Medicine;Jul98, Vol. 66 Issue 7, p29 

    Presents an abstract of the article `Use and Effectiveness of Intravenous Heparin Therapy for Treatment of Acute Myocardial Infarction in the Elderly,' by H. M. Krumholz, J. Hennen, et al from the `Journal of American College Cardiol' dated April 1998.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics